Abstract: West Pharmaceutical posted strong Q1 results, beating expectations with adjusted EPS of $2.13 and revenue of $844.9 million. GLP-1 related revenues, about 10% of sales, fueled momentum and led to a raised 2026 guidance for EPS and sales.Summary: West Pharma beat Q1 expectations with $2.13 adjusted EPS and $844.9M revenue, driven by GLP-1 revenues at 10% of sales, prompting an upward revision to 2026 guidance.

NodeGuardian

2026-04-23 19:26:49

Abstract generation in progress

West Pharmaceutical reported strong Q1 results, exceeding analyst expectations with adjusted EPS of $2.13 and net sales of $844.90 million. The growth was significantly driven by GLP-1 related revenues, contributing 10% to total sales. Consequently, the company raised its fiscal 2026 guidance for both adjusted earnings per share and sales, reflecting continued momentum and market opportunity in oral GLP-1s.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
Gate13thAnniversaryLive
1.25M Popularity
#
WCTCTradingChallengeShare8MUSDT
807.66K Popularity
#
BitcoinBouncesBack
226K Popularity
#
EthereumMemeSeasonReturns
2.01M Popularity
#
USIranTalksProgress
918.33K Popularity

Sitemap

West Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1

Trending Topics

Gate13thAnniversaryLive

WCTCTradingChallengeShare8MUSDT

BitcoinBouncesBack

EthereumMemeSeasonReturns

USIranTalksProgress

Pin